Procainamide HCl (Procainamide HCl) Patent Expiration, LOE Window & CMS Spending
Procainamide HCl (Procainamide HCl) by Pfizer: Multi-Source Generic Molecule, 2 AB generics, $18K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pfizer |
| FDA Application & Pathway | Reconciled (ANDA) |
| Exclusivity / Cliff Horizon | Multi-Source Generic Molecule |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $18K |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $18K |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 367.4% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.